In this article, we will be taking a look at the 10 best mid-cap stocks to buy according to billionaires.
On July 1, Alan McKnight, the CIO at Regions Wealth Management, appeared on CNBC to explain how his biggest worry is currently centered around uncertainty, which he believes leads to volatility. He pointed to the situation in Washington and ongoing trade policy discussions as examples. McKnight emphasized that businesses and investors desire clarity to allocate capital going forward. However, at the same time, McKnight has shown a lot of interest in mid-cap stocks. He noted that mid-caps had taken a bit longer to gain momentum.
Mid-caps and large-caps were about equal in terms of earnings growth. He argued, however, that the present value discrepancy did not fairly represent the potential for mid-caps in the future. According to McKnight, mid-cap firms with solid balance sheets and earnings growth on par with large-caps should start to be valued more like their large-cap peers as the year went on and into the following year.
McKnight went on to explain his stance, saying that investors would profit if mid-cap valuations rose from 17x earnings to somewhere between 20x and 21x earnings. At the very least, he reasoned, earnings would start to rise, which would raise mid-caps’ valuation and earnings. On the other hand, he thought that large-cap stocks had less potential for valuation growth and had a hard time defending higher prices, especially in some industries like the MAG7.
A person with a cell phone who is looking for new stocks
Our Methodology
We started by screening for companies with a market capitalization between $2 billion and $10 billion. From this filtered group, we ranked the stocks based on the number of billionaire investors holding positions, using data from the Insider Monkey database. In cases where multiple stocks had the same number of billionaire holders, we used market capitalization as a tiebreaker, giving a higher rank to the company with the larger market cap.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Here is our list of the 10 best mid-cap stocks to buy according to billionaires.
10. Mesoblast Limited (NASDAQ:MESO)
Number of Billionaire Holdings: 1
Mesoblast Limited (NASDAQ:MESO) is among the best mid-cap stocks to buy according to billionaires. It is a global leader in developing allogeneic (off-the-shelf) cellular medicines using its proprietary mesenchymal lineage cell technology. The company targets severe inflammatory diseases that lack effective treatment options. Its lead product, Ryoncil (remestemcel-L), became the first and only FDA-approved mesenchymal stromal cell therapy for children with steroid-refractory acute graft versus host disease (GVHD) in March 2025. Following approval, Mesoblast Limited (NASDAQ:MESO) rapidly launched the drug, partnering with over 25 major U.S. transplant centers and securing insurance coverage for over 250 million lives, including mandatory Medicaid coverage in all states.
Ryoncil now benefits from seven years of orphan drug exclusivity and biologic exclusivity until 2036, with intellectual property protection through 2044, effectively limiting competition. The approval marks the foundation of the business’s broader pediatric inflammatory disease franchise, with plans to expand Ryoncil’s use to additional pediatric and adult indications.
The corporation’s manufacturing processes allow scalable production of consistent cell therapies without the need for donor-recipient matching, simplifying access and logistics. The company is also advancing other key candidates: Revascor (rexlemestrocel-L) for ischemic heart failure, which is on track for FDA submission by the end of 2025 under RMAT designation, and a Phase 3 program for rexlemestrocel-L targeting chronic discogenic low back pain, offering a non-opioid alternative for patients.
To support its commercialization phase, Mesoblast Limited (NASDAQ:MESO) strengthened its board with the appointment of Lyn Cobley and was recently added to the S&P/ASX 200 Index. With regulatory momentum, market adoption, and strong IP protection, the company is positioning itself as a major innovator in cellular medicine.
9. BW LPG Limited (NYSE:BWLP)
Number of Billionaire Holdings: 4
BW LPG Limited (NYSE:BWLP), headquartered in Singapore and listed on both the Oslo and New York Stock Exchanges, is the world’s leading owner and operator of liquefied petroleum gas (LPG) vessels. Its fleet of over 50 Very Large Gas Carriers (VLGCs) has a combined capacity of more than 4 million cubic meters. Operating across shipping, trading, and infrastructure, the company is known for pioneering LPG dual-fuel engine retrofits to support low-emission maritime transport.
In May 2025, BW LPG Limited (NYSE:BWLP) announced its withdrawal from the planned onshore LPG terminal project in Navi Mumbai, India, marking a strategic refocus on its core competencies, shipping and trading. Despite exiting this infrastructure investment, the company reaffirmed its commitment to India as a key market for energy transition efforts.
The company has continued strengthening its fleet through the acquisition of 12 modern VLGCs from Avance Gas Holdings, including vessels like BW Capella. Alongside fleet expansion, the corporation is actively retrofitting more than 15 ships with LPG dual-fuel technology, supporting international decarbonization goals and ensuring compliance with tightening emissions regulations.
BW LPG Limited (NYSE:BWLP)’s Product Services segment also showed solid performance in Q2 2025, reporting approximately $15 million in gross trading results. This reflects the company’s success in navigating volatile markets and optimizing integrated trading and shipping operations.